Background Ototoxicity is a common adverse side effect of platinum chemotherapy and
cranial radiation therapy; however, individual susceptibility is highly variable. Therefore, our …

Background: Survival rates after childhood cancer now reach nearly 80% in developed
countries. However, treatments that lead to survival and cure can cause serious adverse …

In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment
suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) …

Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin
chemotherapy. The aim of this study is to identify novel genetic variants that play a role in …

Platinum is extensively used in the treatment of several childhood cancers. However,
ototoxicity is one of the most notable adverse effects, especially in children. Several studies …

Ototoxicity is a common side effect of platinum treatment and manifests as irreversible, high-
frequency sensorineural hearing loss. Genetic association studies have suggested a role for …

Background Irreversible sensorineural hearing loss is a common side effect of platinum
treatment with the potential to significantly impair the neurocognitive, social and educational …

Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumours. A
serious complication of cisplatin treatment is permanent hearing loss. The study hypothesis …

Ototoxicity is a debilitating side effect of platinating agents with substantial interpatient
variability. We sought to evaluate the association of thiopurine S‐methyltransferase (TPMT) …

Objectives Cisplatin ototoxicity affects 42–88% of treated children. Catechol-O-
methyltransferase (COMT), thiopurine methyltransferase (TPMT) and AYCP2 genetic …